PURPOSE: Thyroid cancer is the most common malignancy affecting the endocrine glands. The incidence of his malady has conspicuously increased during the recent years. Thyroid diseases affect women approximately 3 times more often than men, and this incidence decreases after menopause. This gender difference has suggested that the female sex steroids stimulate the growth of the thyroid, the same as for the breast. In the present study, we investigated the expressions of estrogen receptor (ER) and progesterone receptor (PR) in thyroid lesions. METHODS: The tissues from 193 human thyroid glands (136 thyroid cancers and 57 adenomatous hyperplasias) were used for the present immunohistochemical assessment of the ER and PR expressions. RESULTS: The incidences of the estrogen and progesterone receptor positive cases were 19.7 and 41.5%, respectively. The incidence of the progesterone receptor positive cases was higher for females (46.5%) than for males (19.4%) however, the expression of estrogen receptor was not different significantly between the females and males. Higher expressions of estrogen and progesterone receptors were detected in the thyroid cancers than in the adenomatous hyperplasias. The PR expression seemed to correlate with the tumor size: a higher PR expression was found in the T3 cancers than in the T2 cancers. CONCLUSION: Our findings provide new insight that the ER and PR expressions may be related to the pathogenesis and progression of thyroid cancer.
Breast ; Endocrine Glands ; Estrogens* ; Female ; Humans ; Hyperplasia ; Incidence ; Male ; Menopause ; Progesterone* ; Receptors, Progesterone* ; Steroids ; Thyroid Diseases ; Thyroid Gland* ; Thyroid Neoplasms ; Thyroid Nodule*

PURPOSE: Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)–positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this studywas conducted to affirm the efficacy and toxicities of letrozole in Korean patients. MATERIALS AND METHODS: This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medicalrecords. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity. RESULTS: The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤ 2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated. CONCLUSION: Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.
Administration, Oral ; Breast Neoplasms* ; Breast* ; Disease Progression ; Disease-Free Survival ; Female ; Humans ; Korea* ; Multivariate Analysis ; Retrospective Studies